A year has passed since the Ministry of Health, Labor and Welfare (MHLW) announced its package strategy to fuel the early commercialization of software as a medical device (SaMD) in November last year. A growing number of drug makers are…
REGULATORY
MOF Panel’s Proposal Urges More Stringent Drug Cost Control, Revisiting of Semi-Automatic Listing
The Fiscal System Council issued its recommendation to the finance minister on May 21 with a view to the government’s FY2022 budget formulation, renewing its calls for “optimizing drug spending” by introducing and boosting fiscal discipline in the reimbursement of…
To read the full story
Related Article
- MOF Calls for Stepwise Cuts in 2% Adjustment Rate, Timeline towards Abolishment
November 9, 2021
- Japan Drug Spending Up 2.3% Annually Since 2000, Outstripping GDP Growth: MOF
November 9, 2021
- Key MOF Official Wants Budget Neutrality, Cap to Optimize Drug Costs
July 20, 2021
- Automatic Listing for Approved Drugs Erodes Financial Predictability: MOF
April 19, 2021
- MOF Panel Issues FY2021 Budget Recommendation, Ups Tone on All-Product Drug Re-Pricing
November 26, 2020
REGULATORY
- Average NHI-Market Price Gap of Listed Drugs at 7.6%: MHLW
December 3, 2021
- Amgen’s KRAS Inhibitor, MSD’s Cough Drug Sail through PAFSC, January Approval Likely
December 3, 2021
- 70% of Pharmacies Procured Alternative Products due to Generic Scandals in FY2020: Chuikyo Survey
December 3, 2021
- Chuikyo Defers Coverage for SaMD for Breast Cancer Recurrence Risk Assessment; Software Remains Incomplete
December 3, 2021
- MHLW Eyes Emergency Approval System Based on “Presumed” Efficacy
December 2, 2021
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…